Prediction of liver cancer treatment efficacy by CTC.

Investigation of Treatment Efficacy Prediction Method for Liver Cancer Using Circulating Tumor Cells (CTC) - PRECISE-HCC: Predicting Response of Efficacy in Circulating Tumor Cells to Immuno-Checkpoint Inhibitor in Hepatocellular Carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1061230098

Enrollment

Registered

2024-02-07

Start date

2024-01-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases of unresectable advanced hepatocellular carcinoma (HCC) for which treatment with immune checkp Hepatocellular carcinoma, Immune checkpoint inhibitors, Circulating tumore cells

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Select patients who meet all of the following criteria: 1) Diagnosed with hepatocellular carcinoma by imaging or histological examination. 2) Patients scheduled to receive treatment with immune checkpoint inhibitors. 3) Men and women aged 20 or older when obtaining consent.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will not be included in this clinical study: 1) Patients with tumors originating from other organs. 2) Others deemed unsuitable as patients by the principal investigator for this study.

Design outcomes

Primary

Measure	Time frame
Blood samples will be collected from patients with unresectable advanced hepatocellular carcinoma (HCC) before and after treatment with immune checkpoint inhibitors (regardless of treatment regimen or line), and circulating tumor cells (CTC) will be measured to verify the usefulness of CTC count in assessing treatment efficacy.	—

Contacts

Public ContactTakaaki Sugihara

Fuculty of Medicine,Tottiri University

sugitaka@tottori-u.ac.jp+81-859387059

Outcome results